Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti CD19 CAR-T cell therapy - Shanghai First Song Therapeutics

Next Previous
X
Search
Drug Profile

Anti CD19 CAR-T cell therapy - Shanghai First Song Therapeutics

Alternative Names: Anti-CD19 CAR-T cell therapy - Shanghai First Song Therapeutics

Latest Information Update: 07 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai First Song Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase 0 Non-Hodgkin's lymphoma
  • Preclinical Autoimmune disorders

Most Recent Events

  • 01 Aug 2024 Phase-0 for Non-Hodgkin's lymphoma (Second-line therapy or greater, In adolescents, In adults, In the elderly) in China (IV) (NCT06532630)
  • 23 May 2024 Preclinical trials in Autoimmune disorders in China(IV), prior to May 2024
  • 14 May 2024 First Affiliated Hospital of Wenzhou Medical University in collaboration with Shanghai First Song Therapeutics plans phase 0 trial in Autoimmune disorders (Treatment experienced) in China (IV) (NCT06420154)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top